Autopsy report · NCT03978156

Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease

“Covid-19. Relocation of trainee/investigator. Covid-19.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 1 year 5 months before it stopped.
• 6 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Yale University

Sponsor type

University, hospital or other

Conditions

Sickle Cell Disease

Interventions

Dronabinol 2.5 MG; Microcrystalline cellulose

Participants

6

Sites

1

Countries

United States

Trials that died the same way

• Efficacy of Two Local Anesthetics on Quality of Life After Endodontic Treatment
  “COVID-19 and Personnel changes” (74% match in meaning)
• Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery
  “COVID-19 challenges to recruitment” (70% match in meaning)
• Acute Effects of the Prostaglandin (Alprostadil) on Cerebral and Pulmonary Flow
  “Covid 19 and difficulty with recruitment” (70% match in meaning)
• Compression Wraps as Adjuvant Therapy in Management of Acute Systolic Heart Failure
  “challenges in recruitment due to covid-19” (69% match in meaning)
• Lidocaine Administration During Flexible Bronchoscopy and Endobronchial Ultrasound
  “COVID lack of cases/recruitment” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.